Digistain gains clinical data to support rapid breast cancer assessment method
Digistain, a company with its roots at Imperial, has proven the worth of its breast cancer assessment method in a significant clinical trial.
Imperial research breakthrough could spare brain cancer patients risky surgery
A simple blood test could help diagnose patients with the deadliest form of brain cancer, sparing them from undergoing invasive, highly-risky surgery.
Meet the team leading the charge against cervical cancer
Cervical Cancer Prevention Week serves as a poignant reminder of the impact this devastating disease can have on women's lives.
Risk of dying from cancer varies widely across regions in England
The risk of dying of cancer in England varies hugely depending on where people live, according to new research led by Imperial.
Largest study of its kind shows leafy greens may decrease bowel cancer risk
Increasing the amount of folate through our diet or taking supplements could help to reduce bowel cancer risk.
Unraveling the Secrets of Zombie cells
A new druggable pathway identified as a target for drugs against cancer and age-related diseases
Prostate cancer focal therapy is cost effective and may improve patient outcomes
Minimally invasive focal therapies for prostate cancer are associated with a lower overall cost and improved quality of life for patients.
New AI tool detects up to 13% more breast cancers than humans alone
A new AI tool from Kheiron Medical Technologies and Imperial College London can detect up to 13% more breast cancers than humans in breast screenings.
Bendy X-rays and DMT infusions: News from Imperial
Here’s a batch of fresh news and announcements from across Imperial.
New funding for research investigating how breast cancer resists hormone therapy
Imperial researchers have received funding from Breast Cancer Now for research into new treatments for breast cancer that resists hormone therapy.
